Clinical Role of Serum Interleukin-17A in the Prediction of Refractory Mycoplasma pneumoniae Pneumonia in Children

References

• Jain S, Williams DJ, Arnold SR, et al. Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med. 2015;372(9):835–845. doi:10.1056/NEJMoa140587025714161
   PubMed Web of Science ®Google Scholar
• Gao LW, Yin J, Hu YH, et al. The epidemiology of paediatric Mycoplasma pneumoniae pneumonia in North China: 2006 to 2016. Epidemiol Infect. 2019;147:e192. doi:10.1017/S095026881900083931364532
   PubMed Web of Science ®Google Scholar
• Meyer Sauteur PM, Unger WWJ, Nadal D, et al. Infection with and carriage of Mycoplasma pneumoniae in children. Front Microbiol. 2016;7:329. doi:10.3389/fmicb.2016.0032927047456
   PubMed Web of Science ®Google Scholar
• Narita M. Classification of extrapulmonary manifestations due to Mycoplasma pneumoniae infection on the basis of possible pathogenesis. Front Microbiol. 2016;7:23. doi:10.3389/fmicb.2016.0002326858701
   PubMed Web of Science ®Google Scholar
• Parrott GL, Kinjo T, Fujita J. A compendium for Mycoplasma pneumoniae. Front Microbiol. 2016;7:513. doi:10.3389/fmicb.2016.0051327148202
   PubMed Web of Science ®Google Scholar
• Olson D, Watkins LK, Demirjian A, et al. Outbreak of Mycoplasma pneumoniae-associated Stevens-Johnson syndrome. Pediatrics. 2015;136(2):e386–e394. doi:10.1542/peds.2015-027826216320
   PubMed Web of Science ®Google Scholar
• Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev. 2004;17(4):697–728. doi:10.1128/CMR.17.4.697-728.200415489344
   PubMed Web of Science ®Google Scholar
• Zheng X, Lee S, Selvarangan R, et al. Macrolide-resistant Mycoplasma pneumoniae, United States. Emerg Infect Dis. 2015;21(8):1470–1472. doi:10.3201/eid2108.15027326196107
   PubMed Web of Science ®Google Scholar
• Eshaghi A, Memari N, Tang P, et al. Macrolide-resistant Mycoplasma pneumoniae in humans, Ontario, Canada, 2010–2011. Emerg Infect Dis. 2013;19(9). doi:10.3201/eid1909.121466
   Web of Science ®Google Scholar
• Brown RJ, Macfarlane-Smith L, Phillips S, et al. Detection of macrolide resistant Mycoplasma pneumoniae in England, September 2014 to September 2015. Euro Surveill. 2015;20(48):30078. doi:10.2807/1560-7917.ES.2015.20.48.3007826675545
   PubMedGoogle Scholar
• Tashiro M, Fushimi K, Kawano K, et al. Comparison of efficacy of antimicrobial agents among hospitalized patients with Mycoplasma pneumoniae pneumonia in Japan during large epidemics of macrolide-resistant M. pneumoniae infections: a nationwide observational study. Clin Infect Dis. 2017;65(11):1837–1842. doi:10.1093/cid/cix69529020161
   PubMed Web of Science ®Google Scholar
• Kawai Y, Miyashita N, Kubo M, et al. Nationwide surveillance of macrolide-resistant Mycoplasma pneumoniae infection in pediatric patients. Antimicrob Agents Chemother. 2013;57(8):4046–4049. doi:10.1128/AAC.00663-1323716043
   PubMed Web of Science ®Google Scholar
• Yamazaki T, Kenri T. Epidemiology of Mycoplasma pneumoniae infections in Japan and therapeutic strategies for Macrolide-resistant M. pneumoniae. Front Microbiol. 2016;7:693. doi:10.3389/fmicb.2016.0069327242718
   PubMed Web of Science ®Google Scholar
• Zhao F, Liu G, Wu J, et al. Surveillance of macrolide-resistant Mycoplasma pneumoniae in Beijing, China, from 2008 to 2012. Antimicrob Agents Chemother. 2013;57(3):1521–1523. doi:10.1128/AAC.02060-1223263003
   PubMed Web of Science ®Google Scholar
• Nakane D, Kenri T, Matsuo L, et al. Systematic structural analyses of attachment organelle in Mycoplasma pneumoniae. PLoS Pathog. 2015;11(12):e1005299. doi:10.1371/journal.ppat.100529926633540
   PubMed Web of Science ®Google Scholar
• Shimizu T. Inflammation-inducing factors of Mycoplasma pneumoniae. Front Microbiol. 2016;7:414. doi:10.3389/fmicb.2016.0041427065977
   PubMed Web of Science ®Google Scholar
• Okumura T, Kawada JI, Tanaka M, et al. Comparison of high-dose and low-dose corticosteroid therapy for refractory Mycoplasma pneumoniae pneumonia in children. J Infect Chemother. 2019;25(5):346–350. doi:10.1016/j.jiac.2019.01.00330718192
   PubMed Web of Science ®Google Scholar
• Luo Z, Luo J, Liu E, et al. Effects of prednisolone on refractory Mycoplasma pneumoniae pneumonia in children. Pediatr Pulmonol. 2014;49(4):377–380. doi:10.1002/ppul.2275223401275
   PubMed Web of Science ®Google Scholar
• Miyashita N, Kawai Y, Inamura N, et al. Setting a standard for the initiation of steroid therapy in refractory or severe Mycoplasma pneumoniae pneumonia in adolescents and adults. J Infect Chemother. 2015;21(3):153–160. doi:10.1016/j.jiac.2014.10.00825533771
   PubMed Web of Science ®Google Scholar
• Youn YS, Lee SC, Rhim JW, et al. Early additional immune-modulators for Mycoplasma pneumoniae pneumonia in children: an observation study. Infect Chemother. 2014;46(4):239–2247. doi:10.3947/ic.2014.46.4.23925566403
   PubMedGoogle Scholar
• Zhang Y, Chen Y, Chen Z, et al. Effects of bronchoalveolar lavage on refractory Mycoplasma pneumoniae pneumonia. Respir Care. 2014;59(9):1433–1439. doi:10.4187/respcare.0303224962224
   PubMed Web of Science ®Google Scholar
• Gallego M, Pomares X, Capilla S, et al. C-reactive protein in outpatients with acute exacerbation of COPD: its relationship with microbial etiology and severity. Int J Chron Obstruct Pulmon Dis. 2016;11:2633–2640. doi:10.2147/COPD.S11712927799762
   PubMed Web of Science ®Google Scholar
• Shrotriya S, Walsh D, Bennani-baiti N, et al. C-Reactive protein is an important biomarker for prognosis tumor recurrence and treatment response in adult solid tumors: a systematic review. PLoS One. 2015;10(12):e0143080. doi:10.1371/journal.pone.014308026717416
   PubMed Web of Science ®Google Scholar
• Alkhateeb AA, Connor JR. The significance of ferritin in cancer: anti-oxidation, inflammation and tumorigenesis. Biochim Biophys Acta. 2013;1836(2):245–254. doi:10.1016/j.bbcan.2013.07.00223891969
   PubMed Web of Science ®Google Scholar
• Shen J, Chen Z, Zhuang Q, et al. Prognostic value of serum lactate dehydrogenase in renal cell carcinoma: a systematic review and meta-analysis. PLoS One. 2016;11(11):e0166482. doi:10.1371/journal.pone.016648227861542
   PubMed Web of Science ®Google Scholar
• Duman A, Akoz A, Kapci M, et al. Prognostic value of neglected biomarker in sepsis patients with the old and new criteria: predictive role of lactate dehydrogenase. Am J Emerg Med. 2016;34(11):2167–2171. doi:10.1016/j.ajem.2016.06.01227599399
   PubMed Web of Science ®Google Scholar
• Akdis M, Aab A, Altunbulakli C, et al. Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β, and TNF-α: receptors, functions, and roles in diseases. J Allergy Clin Immunol. 2016;138(4):984–1010. doi:10.1016/j.jaci.2016.06.03327577879
   PubMed Web of Science ®Google Scholar
• Seo YH, Kim JS, Seo SC, et al. Predictive value of C-reactive protein in response to macrolides in children with macrolide-resistant Mycoplasma pneumoniae pneumonia. Korean J Pediatr. 2014;57(4):186–192. doi:10.3345/kjp.2014.57.4.18624868216
   PubMedGoogle Scholar
• Kawamata R, Yokoyama K, Sato M, et al. Utility of serum ferritin and lactate dehydrogenase as surrogate markers for steroid therapy for Mycoplasma pneumoniae pneumonia. J Infect Chemother. 2015;21(11):783–789. doi:10.1016/j.jiac.2015.07.00926298038
   PubMed Web of Science ®Google Scholar
• Choi YJ, Jeon JH, Oh JW. Critical combination of initial markers for predicting refractory Mycoplasma pneumoniae pneumonia in children: a case control study. Respir Res. 2019;20(1):193. doi:10.1186/s12931-019-1152-531443650
   PubMed Web of Science ®Google Scholar
• Li Q, Gu Y, Tu Q, et al. Blockade of Interleukin-17 restrains the development of acute lung injury. Scand J Immunol. 2016;83(3):203–211. doi:10.1111/sji.1240826709006
   PubMed Web of Science ®Google Scholar
• Yang M, Meng F, Wang K, et al. Interleukin 17A as a good predictor of the severity of Mycoplasma pneumoniae pneumonia in children. Sci Rep. 2017;7(1):12934. doi:10.1038/s41598-017-13292-529021577
   PubMed Web of Science ®Google Scholar
• Harris M, Clark J, Coote N, et al. British thoracic society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax. 2011;66(Suppl 2):ii1–ii23. doi:10.1136/thoraxjnl-2011-20059821903691
   PubMed Web of Science ®Google Scholar
• Tamura A, Matsubara K, Tanaka T, et al. Methylprednisolone pulse therapy for refractory Mycoplasma pneumoniae pneumonia in children. J Infect. 2008;57(3):223–228. doi:10.1016/j.jinf.2008.06.01218656264
   PubMed Web of Science ®Google Scholar
• Liu W, Peng L, Hua S. Clinical significance of dynamic monitoring of blood lactic acid, oxygenation index and C-reactive protein levels in patients with severe pneumonia. Exp Ther Med. 2015;10(5):1824–1828. doi:10.3892/etm.2015.277026640556
   PubMed Web of Science ®Google Scholar
• Agnello L, Bellia C, Di Gangi M, et al. Utility of serum procalcitonin and C-reactive protein in severity assessment of community-acquired pneumonia in children. Clin Biochem. 2016;49(1–2):47–50. doi:10.1016/j.clinbiochem.2015.09.00826386341
   PubMed Web of Science ®Google Scholar
• Xiao X, Xue L, Sheng HL, et al. Correlation between serum levels of C-reactive protein and infant pneumonia: a meta-analysis. Exp Ther Med. 2015;9(6):2331–2338. doi:10.3892/etm.2015.241726136982
   PubMed Web of Science ®Google Scholar
• Recalcati S, Invernizzi P, Arosio P, et al. New functions for an iron storage protein: the role of ferritin in immunity and autoimmunity. J Autoimmun. 2008;30(1–2):84–89. doi:10.1016/j.jaut.2007.11.00318191543
   PubMed Web of Science ®Google Scholar
• Koperdanova M, Cullis JO. Interpreting raised serum ferritin levels. BMJ. 2015;351:h3692. doi:10.1136/bmj.h369226239322
   PubMed Web of Science ®Google Scholar
• Isoda K, Takeuchi T, Kotani T, et al. Pre-treatment ferritin level and alveolar-arterial oxygen gradient can predict mortality rate due to acute/subacute interstitial pneumonia in dermatomyositis treated by cyclosporine a/glucocorticosteroid combination therapy: a case control study. PLoS One. 2014;9(2):e89610. doi:10.1371/journal.pone.008961024586910
   PubMed Web of Science ®Google Scholar
• Liu TY, Lee WJ, Tsai CM, et al. Serum lactate dehydrogenase isoenzymes 4 plus 5 is a better biomarker than total lactate dehydrogenase for refractory Mycoplasma pneumoniae pneumonia in children. Pediatr Neonatol. 2018;59(5):501–506. doi:10.1016/j.pedneo.2017.12.00829337082
   PubMed Web of Science ®Google Scholar
• Lu A, Wang C, Zhang X, et al. Lactate dehydrogenase as a biomarker for prediction of refractory Mycoplasma pneumoniae pneumonia in children. Respir Care. 2015;60(10):1469–1475. doi:10.4187/respcare.0392026060318
   PubMed Web of Science ®Google Scholar
• Inamura N, Miyashita N, Hasegawa S, et al. Management of refractory Mycoplasma pneumoniae pneumonia: utility of measuring serum lactate dehydrogenase level. J Infect Chemother. 2014;20(4):270–273. doi:10.1016/j.jiac.2014.01.00124486173
   PubMed Web of Science ®Google Scholar
• Tanaka H, Narita M, Teramoto S, et al. Role of interleukin-18 and T-helper type 1 cytokines in the development of Mycoplasma pneumoniae pneumonia in adults. Chest. 2002;121(5):1493–1497. doi:10.1378/chest.121.5.149312006434
   PubMed Web of Science ®Google Scholar
• Kirkham BW, Kavanaugh A, Reich K. Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology. 2014;141(2):133–142. doi:10.1111/imm.1214223819583
   PubMed Web of Science ®Google Scholar
• Sun C, Kono H, Furuya S, et al. Interleukin-17A plays a pivotal role in chemically induced hepatocellular carcinoma in mice. Dig Dis Sci. 2016;61(2):474–488. doi:10.1007/s10620-015-3888-126467699
   PubMed Web of Science ®Google Scholar
• Wang Y, Wu H, Wu X, et al. Interleukin 17A promotes gastric cancer invasiveness via NF-κB mediated matrix metalloproteinases 2 and 9 expression. PLoS One. 2014;9(6):e96678. doi:10.1371/journal.pone.009667824905806
   PubMed Web of Science ®Google Scholar
• Wei L, Wang H, Yang F, et al. Interleukin-17 potently increases non-small cell lung cancer growth. Mol Med Rep. 2016;13(2):1673–1680. doi:10.3892/mmr.2015.469426708832
   PubMed Web of Science ®Google Scholar
• Ding W, Zhang XY, Pan M, et al. Interleukin-17A promotes the formation of inflammation in the lung tissues of rats with pulmonary fibrosis. Exp Ther Med. 2015;10(2):491–497. doi:10.3892/etm.2015.256426622342
   PubMed Web of Science ®Google Scholar
• Chen K, Kolls JK. Interleukin-17A (IL17A). Gene. 2017;614:8–14. doi:10.1016/j.gene.2017.01.01628122268
   PubMed Web of Science ®Google Scholar
• Yasuda K, Nakanishi K, Tsutsui H. Interleukin-18 in health and disease. Int J Mol Sci. 2019;20(3):649. doi:10.3390/ijms20030649
   PubMed Web of Science ®Google Scholar
• Wynn JL, Wilson CS, Hawiger J, et al. Targeting IL-17A attenuates neonatal sepsis mortality induced by IL-18. Proc Natl Acad Sci USA. 2016;113(19):E2627–E2635. doi:10.1073/pnas.151579311327114524
   PubMed Web of Science ®Google Scholar